文献速递产科母胎医学

英格兰分娩时SARS-CoV-2感染孕妇的母婴结局:全国队列研究

Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-20

该研究基于英格兰全国住院数据库,纳入2020年5月29日至2021年1月31日单胎分娩孕妇342,080例,其中3527例分娩时实验室确诊SARS-CoV-2感染。调整混杂因素后,感染与胎儿死亡、早产、子痫前期/子痫、紧急剖宫产及产后住院延长风险升高相关;足月分娩的新生儿除住院延长外,其他不良结局无显著差异。

要点

  • 分娩时SARS-CoV-2感染与胎儿死亡(aOR 2.21)、早产(aOR 2.17)风险升高相关。
  • 感染孕妇子痫前期/子痫(aOR 1.55)和紧急剖宫产(aOR 1.63)风险显著增加。
  • 足月分娩新生儿除住院延长(21.1% vs 14.6%)外,其他不良结局无显著差异。

核心结论

  • 分娩时SARS-CoV-2感染与胎儿死亡、早产、子痫前期和紧急剖宫产率升高相关。
  • 除与早产相关的结局外,新生儿未出现额外不良结局。
  • 应就SARS-CoV-2感染风险对孕妇进行咨询,并考虑优先接种疫苗。

研究设计与样本

  • 基于英格兰全国住院数据库的人群队列研究。
  • 纳入2020年5月29日至2021年1月31日单胎分娩孕妇342,080例,其中3527例实验室确诊SARS-CoV-2感染。
  • 采用逻辑回归计算调整比值比(aOR)及95%置信区间,调整母亲年龄、种族、产次、孕前糖尿病、孕前高血压及贫困指数。

主要发现

  • 胎儿死亡aOR 2.21(95%CI 1.58-3.11,P<.001),早产aOR 2.17(95%CI 1.96-2.42,P<.001)。
  • 子痫前期/子痫aOR 1.55(95%CI 1.29-1.85,P<.001),紧急剖宫产aOR 1.63(95%CI 1.51-1.76,P<.001)。
  • 产后住院延长aOR 1.57(95%CI 1.44-1.72,P<.001)。
  • 新生儿不良结局aOR 1.45(95%CI 1.27-1.66,P<.001),需专科新生儿护理aOR 1.24(95%CI 1.02-1.51,P=.03),新生儿住院延长aOR 1.61(95%CI 1.49-1.75,P<.001)。
  • 足月分娩(≥37周)分析中,新生儿不良结局(P=.78)、专科护理(P=.22)和4周内再入院(P=.05)无显著差异;但住院延长仍有差异(21.1% vs 14.6%,aOR 1.61,95%CI 1.49-1.75,P<.001)。

临床怎么用

  • 对孕妇应告知SARS-CoV-2感染相关的胎儿死亡、早产、子痫前期和紧急剖宫产风险。
  • 应考虑将孕妇列为疫苗接种优先人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some studies have suggested that women with SARS-CoV-2 infection during pregnancy are at increased risk of adverse pregnancy and neonatal outcomes, but these associations are still not clear. OBJECTIVE: This study aimed to determine the association between SARS-CoV-2 infection at the time of birth and maternal and perinatal outcomes. STUDY DESIGN: This is a population-based cohort study in England. The inclusion criteria were women with a recorded singleton birth between May 29, 2020, and January 31, 2021, in a national database of hospital admissions. Maternal and perinatal outcomes were compared between pregnant women with a laboratory-confirmed SARS-CoV-2 infection recorded in the birth episode and those without. Study outcomes were fetal death at or beyond 24 weeks' gestation (stillbirth), preterm birth (<37 weeks' gestation), small for gestational age infant (small for gestational age; birthweight at the <tenth centile), preeclampsia or eclampsia, induction of labor, mode of birth, specialist neonatal care, composite neonatal adverse outcome indicator, maternal and neonatal length of hospital stay after birth (3 days or more), and 28-day neonatal and 42-day maternal hospital readmission. Adjusted odds ratios and their 95% confidence interval for the association between SARS-CoV-2 infection status and outcomes were calculated using logistic regression, adjusting for maternal age, ethnicity, parity, preexisting diabetes mellitus, preexisting hypertension, and socioeconomic deprivation measured using the Index of Multiple Deprivation 2019. Models were fitted with robust standard errors to account for hospital-level clustering. The analysis of the neonatal outcomes was repeated for those born at term (≥37 weeks' gestation) because preterm birth has been reported to be more common in pregnant women with SARS-CoV-2 infection. RESULTS: The analysis included 342,080 women, of whom 3527 had laboratory-confirmed SARS-CoV-2 infection. Laboratory-confirmed SARS-CoV-2 infection was more common in women who were younger, of non-White ethnicity, primiparous, or residing in the most deprived areas or had comorbidities. Fetal death (adjusted odds ratio, 2.21; 95% confidence interval, 1.58-3.11; P<.001) and preterm birth (adjusted odds ratio, 2.17; 95% confidence interval, 1.96-2.42; P<.001) occurred more frequently in women with SARS-CoV-2 infection than those without. The risk of preeclampsia or eclampsia (adjusted odds ratio, 1.55; 95% confidence interval, 1.29-1.85; P<.001), birth by emergency cesarean delivery (adjusted odds ratio, 1.63; 95% confidence interval, 1.51-1.76; P<.001), and prolonged admission after birth (adjusted odds ratio, 1.57; 95% confidence interval, 1.44-1.72; P<.001) were significantly higher for women with SARS-CoV-2 infection than those without. There were no significant differences (P>.05) in the rate of other maternal outcomes. The risk of neonatal adverse outcome (adjusted odds ratio, 1.45; 95% confidence interval, 1.27-1.66; P<.001), need for specialist neonatal care (adjusted odds ratio, 1.24; 95% confidence interval, 1.02-1.51; P=.03), and prolonged neonatal admission after birth (adjusted odds ratio, 1.61; 95% confidence interval, 1.49-1.75; P<.001) were all significantly higher for infants with mothers with laboratory-confirmed SARS-CoV-2 infection. When the analysis was restricted to pregnancies delivered at term (≥37 weeks), there were no significant differences in neonatal adverse outcome (P=.78), need for specialist neonatal care after birth (P=.22), or neonatal readmission within 4 weeks of birth (P=.05). Neonates born at term to mothers with laboratory-confirmed SARS-CoV-2 infection were more likely to have prolonged admission after birth (21.1% compared with 14.6%; adjusted odds ratio, 1.61; 95% confidence interval, 1.49-1.75; P<.001). CONCLUSION: SARS-CoV-2 infection at the time of birth is associated with higher rates of fetal death, preterm birth, preeclampsia, and emergency cesarean delivery. There were no additional adverse neonatal outcomes, other than those related to preterm delivery. Pregnant women should be counseled regarding risks of SARS-CoV-2 infection and should be considered a priority for vaccination.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gurol-Urganci I, Jardine JE, Carroll F, et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol. 2021. PMID: 34023315. doi:10.1016/j.ajog.2021.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。